NCT06973772 - Trial to Evaluate the Immunogenicity and Safety of the Co-administration of Live Attenuated Dengue and Chikungunya Vaccines Compared to Separate Administration in Adults Aged 18 to 59 Years. | Biotech Hunter

Enrollment

900

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

July 31, 2026

Study Completion Date

October 31, 2026

Conditions

DengueChikungunya

Interventions

BIOLOGICAL

DENGUE: Dengue 1,2,3,4 (attenuated) vaccine CHIKUNGUNYA: Chikungunya (CHIKV) live attenuated vaccine (VLA1555)

DENGUE: Dose 10\^2.5-4.1 PFU per virus (1,2,3,4) Route: Subcutaneous CHIKUNGUNYA: Dose \>= 3.0 log TCID50 per 0.5 mL Route: Intramuscular

BIOLOGICAL

DENGUE: Dengue 1,2,3,4 (attenuated) vaccine

DENGUE: Dose 10\^2.5-4.1 PFU per virus (1,2,3,4) Route: Subcutaneous

BIOLOGICAL

Chikungunya (CHIKV) live attenuated vaccine (VLA1555)

CHIKUNGUNYA: Dose \>= 3.0 log TCID50 per 0.5 mL Route: Intramuscular

Trial Locations (7)

Centro Médico de São Francisco, Curitiba

Centro de Pesquisa Inova, Toledo

Hospital São Vicente de Paulo, Passo Fundo

Hospital Escola da Universidade Federal de Pelotas, Pelotas

Reumacenter, Porto Alegre

UBEA - União Brasileira de Educação e Assistência Hospital São Lucas da PUCRS, Porto Alegre

Instituto de Pesquisa em AIDS do Estado do Rio Grande do Sul - IPARGS, Porto Alegre